仟源醫藥(300254.SZ):與晶雲藥物簽署戰略合作協議
格隆匯 9 月 28日丨仟源醫藥(300254.SZ)公佈,為了進一步增強公司藥物研發和盈利能力,根據公司發展戰略並結合實際情況,公司於2020年9月25日召開了第四屆董事會第十三次會議審議通過《關於公司簽署<戰略合作協議>的議案》,董事會同意公司與蘇州晶雲藥物科技股份有限公司(“晶雲藥物”)簽署了《戰略合作協議》。
晶雲藥物是一家專注於藥物晶型研發服務和晶型技術產業化的創新型企業,擁有豐富的晶型研發和製劑研發領域的技術和經驗優勢。晶雲藥物向全球製藥企業提供專業化的藥物晶型研發解決方案,幫助其加速藥物研發進度,為產品質量提供可靠的技術保障。晶雲藥物已主導或參與了全球500多家客户的超過1,000個化合物的晶型研發,合作對象包括了眾多全球知名的大型製藥企業和國內從事1類新藥研發的公司。同時,晶雲藥物充分發揮自身在晶型研發領域的技術和經驗優勢,選取具有較高市場價值、技術門檻和專利壁壘的藥物品種,進行創新晶型技術及產品開發。晶雲藥物已成功開發超過70個藥物品種的創新晶型,適應症涵蓋癌症、自身免疫、心腦血管、血液和神經系統等市場需求巨大的疾病領域,已成功支持和完成了數個美國和中國市場的原料藥和首仿藥的開發和申報。
基於甲乙雙方在各自領域的優勢,甲乙雙方決定在利用創新晶型技術及製劑技術開發中國及美國市場首仿藥及高端仿製藥方面建立緊密合作,甲方可依託乙方技術優勢、國際市場申報經驗,同步佈局國內和國際市場,不斷開發出具有較高專利和技術壁壘的仿製藥,豐富仟源醫藥產品線,加強仟源醫藥的核心競爭力與市場地位,乙方可藉助甲方專業的國內市場研發、生產、營銷能力及經驗,將更多的創新晶型技術及製劑技術成果實現商業轉化,利用創新技術改變製藥行業,讓人們早日用上高質量藥物。
申請藥品專利不僅是保護公司利益的合法手段,也是公司在市場競爭中採用的常見防禦性策略。對於申請時間通常靠後的晶型專利可在藥物化合物專利到期後繼續保護藥物,從而繼續維持藥物的專利壁壘,享受“晶型專利紅利期”。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.